How common is hair loss on Mounjaro, and will it last?

Does Mounjaro actually cause hair loss, or is something else going on?

The honest answer is: probably both at once. Tirzepatide's prescribing information does list alopecia (hair loss) as a recorded side effect, with rates in the Mounjaro SmPC on the eMC sitting around 5–6% at the highest doses tested in the SURMOUNT programme. But that figure needs context. When the body loses weight quickly (which Mounjaro often produces) it can trigger a well-described process called telogen effluvium. Normally, each hair follicle cycles through growth and rest phases independently, so you shed a steady 50–100 hairs a day without noticing. Rapid weight loss, a sharp drop in calories, or a sudden change in nutritional status can push a large proportion of follicles into the resting (telogen) phase simultaneously. Two to four months later, all those hairs shed at once, and the timing lands squarely in the period when people are also attributing everything to the medication they started. This is not to say tirzepatide plays no role at all: metabolic shifts and hormonal changes driven by weight loss may contribute independently. The practical upshot, though, is that the mechanism matters for what you do next. If the cause is rapid weight loss, managing the pace and protecting nutrition are the levers, not stopping treatment.

You can read a broader picture of what happens with hair loss on Mounjaro in our dedicated guide.

Who is most likely to notice hair thinning during treatment?

Not everyone on tirzepatide experiences this, and the pattern in clinical data suggests a few factors tip the balance. People losing weight rapidly (which tends to happen at higher doses or in the early months of treatment) are more likely to notice shedding. Those with already low protein intake, iron deficiency, thyroid dysfunction, or a history of hair thinning are at greater baseline risk. The body is remarkably conservative about where it spends resources when under a calorie deficit: hair follicles are not classed as essential, so production slows when the body perceives nutritional stress. Women, particularly those with a tendency toward diffuse hair thinning, report it more often. It is also worth knowing that some people going through rapid hormonal changes (perimenopause, for example) may find the timing coincides with treatment, making it harder to separate causes. If you have concerns about any of this, the full side-effect profile of Mounjaro covers the broader pattern, and a prescriber can look at your individual picture. One thing our team hears fairly regularly: people assume the shed will be permanent, panic, and stop treatment. In the majority of cases, that is not what the evidence shows.

What actually helps, and when should you speak to a prescriber?

For most people, the shed slows on its own once the body adapts to the new weight and calorie level, usually within three to six months. Practical steps that appear to reduce severity (while making clinical sense given the mechanism) include keeping protein intake adequate even as overall calories fall (aim for the level your prescriber recommends, not the lowest amount you can manage), staying well hydrated, and not dramatically restricting fat alongside calories. Some people find a daily multivitamin with iron and biotin useful if dietary variety has narrowed, though evidence for supplements as a hair-loss treatment is modest. There are more specific tips on managing hair loss while on treatment if you want practical detail.

You should speak to your GP or prescriber promptly if: shedding is severe or accelerating after six months; you notice patchy, rather than diffuse, loss (which suggests a different mechanism entirely); your scalp is itchy, inflamed or sore; or the loss is accompanied by other symptoms such as fatigue, cold intolerance or unexpected weight changes that might point to thyroid or iron issues. Any suspected side effect from a medicine can also be reported directly through the MHRA's Yellow Card scheme, that reporting helps build the evidence base for everyone who uses these medicines in the future.

Is hair loss a reason to stop Mounjaro?

For the vast majority of people, no. Temporary telogen effluvium does not cause permanent follicle damage. The hair that sheds during this phase is hair that would have cycled out anyway, the follicles remain intact, and regrowth follows. Stopping a treatment that is producing real health benefits because of a temporary shed is a decision worth making only with your prescriber's input, weighing the full picture. If you are weighing up how to approach treatment and what the realistic side-effect profile looks like, the data on how often Mounjaro side effects occur gives a useful frame. The more significant and urgent side effects to know about, including how common pancreatitis is with Mounjaro, which the MHRA highlighted in a specific Drug Safety Update in January 2026, are covered in our Mounjaro side effects overview. Severe, persistent abdominal pain that reaches the back is the sign that needs urgent medical attention, not a wait-and-see approach. Hair shedding sits in an entirely different category of concern, real, worth monitoring, but in most cases manageable without stopping treatment.